Cisar J, Kabat E A, Dorner M M, Liao J
J Exp Med. 1975 Aug 1;142(2):435-59. doi: 10.1084/jem.142.2.435.
Binding constants of the dextran-reactive BALB/c mouse IgA myeloma proteins W3129 and QUPC 52 have been determined for each member of the isomaltose series of oligosaccharides and for methyl alphaDglucoside. Protein W3129 has maximum complementarity for isomaltopentaose (IM5) deltaf degrees = 7,180 cal/mol) with 55-60% of the total binding energy directed against methylalphaDglucoside. Protein QUPC 52 gives maximum binding with isomaltohexaose (IM6) (deltaF degrees = -5,340 cal/mol) and has about 70% of its total binding energy for isomaltotriose (IM3), but at most only 5% for isomaltose (IM2) or methyl alphaDglucoside. Protein W3129 precipitates with branched dextrans high in alpha (1 yields 6) linkages and reacts with but does not precipitate a synthetic alpha (1 yields 6)-linked linear dextran. Protein QUPC 52 precipitates both branched and linear dextrans. Thus, the immunodominant group for protein W3129 is mimicked by methyl alphaDglucoside and this protein reacts exclusively at the terminal nonreducing ends of alpha (1 yields 6)-linked dextran chains. Protein QUPC 52 has an immunodominant group which is expressed by IM3 but not smaller oligosaccharides and this protein can react at nonterminal locations along alpha (1 yields 6)-linked dextran chains. Precipitation of linear dextran seems to be a valid although not quantitative assay for antidextrans with nonterminal specificity. Quantitative precipitin reactions with branched and linear dextrans suggest that alpha (1 yields 6)-specific human antidextrans are mixtures of molecules having terminal and nonterminal specificities and that the fraction of each type can vary among individuals. Rabbit antisera against IM3 or IM6 coupled to bovine serum albumin also appear to contain antibodies with nonterminal specificity for dextran chains although a large fraction has terminal specificity. Low molecular weight clinical dextran N-150N (congruent to 60,000) reacted more like linear dextran than like its parent native-branched dextran B512. This is thought to result from an abundance of nonterminal determinants in clinical dextran N-150N but a very small number of functional terminal determinants per molecule. An appreciation of terminal and nonterminal specificities and of the different immunodominant structures in isomaltosyl chains has proven to be of a great value in understanding the immunochemical reactions of dextrans. Moreover, certain previous findings with fructosan-reactive mouse myeloma proteins and human antilevans (55, 84) also suggest terminal and nonterminal specificities for levan chains.
已测定了葡聚糖反应性BALB/c小鼠IgA骨髓瘤蛋白W3129和QUPC 52与异麦芽糖系列寡糖的每个成员以及甲基α-D-葡萄糖苷的结合常数。蛋白W3129与异麦芽五糖(IM5)具有最大互补性(ΔF° = 7180 cal/mol),其总结合能的55 - 60%针对甲基α-D-葡萄糖苷。蛋白QUPC 52与异麦芽六糖(IM6)结合最强(ΔF° = -5340 cal/mol),其总结合能的约70%用于异麦芽三糖(IM3),但用于异麦芽糖(IM2)或甲基α-D-葡萄糖苷的最多仅5%。蛋白W3129能与α(1→6)键含量高的支链葡聚糖沉淀,与合成的α(1→6)连接的线性葡聚糖反应但不沉淀。蛋白QUPC 52能沉淀支链和线性葡聚糖。因此,蛋白W3129的免疫显性基团可被甲基α-D-葡萄糖苷模拟,该蛋白仅在α(1→6)连接的葡聚糖链的末端非还原端反应。蛋白QUPC 52具有一个免疫显性基团,由IM3表达而较小的寡糖不表达,该蛋白可在α(1→6)连接的葡聚糖链的非末端位置反应。线性葡聚糖的沉淀似乎是一种有效的(尽管不是定量的)检测具有非末端特异性的抗葡聚糖的方法。与支链和线性葡聚糖的定量沉淀反应表明,α(1→6)特异性的人抗葡聚糖是具有末端和非末端特异性的分子混合物,且每种类型的比例在个体间可能不同。针对与牛血清白蛋白偶联的IM3或IM6的兔抗血清似乎也含有对葡聚糖链具有非末端特异性的抗体,尽管很大一部分具有末端特异性。低分子量临床葡聚糖N - 150N(约60000)的反应更像线性葡聚糖而不像其母体天然支链葡聚糖B512。这被认为是由于临床葡聚糖N - 150N中存在大量非末端决定簇,但每个分子中功能性末端决定簇的数量非常少。认识到末端和非末端特异性以及异麦芽糖基链中不同的免疫显性结构在理解葡聚糖的免疫化学反应方面已被证明具有很大价值。此外,先前关于果聚糖反应性小鼠骨髓瘤蛋白和人抗果聚糖的某些发现(5, 84)也表明果聚糖链具有末端和非末端特异性。